Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NNMT | P40261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886594 | 1.00 | P4HTM (0.58) | P4HTMFFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL27513663 | 0.90 | FFAR4 (0.58) | P4HTMFFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL1840673 | 0.88 | MKNK1 (0.56) | FFAR1FFAR4LMNAL3MBTL1GPR183 | |
| SCHEMBL5760402 | 0.85 | KDM4E (0.47) | LMNANNMTMEN1KMT2AGPR183 | |
| SCHEMBL2865551 | 0.85 | NNMT (0.54) | P4HTMFFAR1LMNANNMTMEN1 | |
| SCHEMBL2491663 | 0.83 | GABRP (0.56) | P4HTMLMNANNMTMEN1KMT2A | |
| SCHEMBL29589262 | 0.83 | GABRP (0.56) | P4HTMLMNANNMTMEN1KMT2A | |
| SCHEMBL2870123 | 0.83 | NNMT (0.44) | P4HTMFFAR1LMNANNMTMEN1 | |
| SCHEMBL20665279 | 0.83 | CYP24A1 (0.49) | P4HTMFFAR1LMNANNMTMEN1 | |
| SCHEMBL6307266 | 0.81 | CYP4F2 (0.56) | FFAR1LMNAL3MBTL1NNMTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167933-B | As αVAzole amides and amines as integrin inhibitors | 百时美施贵宝公司 | 2022-06-21 | — | — | CN | claimed |
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| WO-2022138791-A1 | EP2 ANTAGONIST | 小野薬品工業株式会社 | 2022-06-30 | — | — | WO | disclosed |
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3807264-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2021-04-21 | — | — | EP | disclosed |
| EP-3027593-B1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
| EP-3116862-B1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-04-17 | — | — | EP | disclosed |
| US-7074930-B2 | Amine salts of an integrin receptor antagonist | MERCK & CO., INC (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1444231-A4 | AMINE SALTS OF AN INTEGRIN RECEPTOR ANTAGONIST | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6953803-B1 | 1-[(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)]-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one; enzyme inhibitors of lipoprotein associated phospholipase A2 (Lp-PLA2); atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20040249158-A1 | Amine salts of an integrin receptor antagonist | MERCK & CO., INC. | 2004-12-09 | — | — | US | disclosed |
| EP-1444231-A1 | AMINE SALTS OF AN INTEGRIN RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1252162-A4 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2003040143-A1 | AMINE SALTS OF AN INTEGRIN RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1252162-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001053297-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| US-4649141-A | HISTAMINE ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | P4HTM 2285/4885FFAR1 1950/4885FFAR4 2590/4885 |
| US-20040249158-A1 | Amine salts of an integrin receptor antagonist | ITGB3, ITGA1, ITGAL | P4HTM 2639/4885FFAR1 104/4885FFAR4 130/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | P4HTM 2285/4885FFAR1 1950/4885FFAR4 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.